Common painkillers lower levels of prostate cancer biomarker

But impact on a man's risk for getting prostate cancer is unclear, physicians say

09-Sep-2008 - USA

Common painkillers like aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker widely used by physicians to help gauge whether a man is at risk of prostate cancer. But the authors of the study, which appears in the journal Cancer, caution that men shouldn't take the painkillers in an effort to prevent prostate cancer just yet.

"We showed that men who regularly took certain medications like aspirin and other non-steroidal anti-inflammatory drugs, or NSAIDS, had a lower serum PSA level," said first author Eric A. Singer, M.D., M.A., a urology resident at the University of Rochester Medical Center. "But there's not enough data to say that men who took the medications were less likely to get prostate cancer. This was a limited study, and we do not know how many of those men actually got prostate cancer."

Singer's team studied the records of 1319 men over the age of 40 who took part in the 2001-2002 National Health and Nutrition Examination Survey (NHANES), a health census conducted by the Centers for Disease Control and Prevention. The team looked at the men's use of NSAIDs such as aspirin and ibuprofen, as well as the painkiller acetaminophen, and at their PSA levels. A man's level of PSA, or prostate-specific antigen, is one of many clues that physicians watch to gauge a man's risk of getting prostate cancer.

The team found that men who used NSAIDs regularly had PSA levels about 10 percent lower compared to men who did not. The team made a similar observation with acetaminophen, but the result was not statistically significant due to the lower number of men in the study taking the medication. While it might be easy to assume that a lowered PSA level automatically translates to a lowered risk of prostate cancer, the authors stress that it's too soon to draw that conclusion.

"While our results are consistent with other research that indicates that certain painkillers may reduce a man's risk of getting prostate cancer, the new findings are preliminary and don't prove a link," said corresponding author Edwin van Wijngaarden, Ph.D., assistant professor in the Department of Community and Preventive Medicine.

Singer said that a man's PSA level can be elevated for reasons unrelated to cancer. Sometimes, for instance, while inflammation is part of a cancer process, sometimes it is not, and so it's possible that a lowered PSA reflects reduced inflammation without affecting a man's risk of prostate cancer. Another possibility is that a PSA level lowered by NSAIDs might artificially mask a man's risk of getting prostate cancer: The medications might lower the PSA, but a man's risk might stay precisely the same.

"More than anything, these findings underscore the importance for doctors to know what medications their patients are on," said Singer, who is chief Urology resident at the University of Rochester Medical Center. "For instance, there are medications commonly used to treat an enlarged prostate that can result in a decreased PSA, and most physicians know that. Doctors should also be asking about patients' use of NSAIDs such as aspirin and ibuprofen."

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Neovacs to expand clinical testing of its TNF-alpha Kinoid lead product candidate

New approach to the sensible utilisation of carbon dioxide from car exhaust gases - "A method has been discovered that uses impure CO2 streams and enables a breakthrough in the synthesis of valuable chemicals and pharmaceuticals"

New approach to the sensible utilisation of carbon dioxide from car exhaust gases - "A method has been discovered that uses impure CO2 streams and enables a breakthrough in the synthesis of valuable chemicals and pharmaceuticals"

Acambis completes enrollment of Phase 3 JE vaccine trials ahead of schedule

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

American Peptide Company Announces Expansion of Its GMP Manufacturing Facility - Company expands capacity to accommodate large scale peptide production for growing customer base

New biotech company Confo Therapeutics launched by VIB and Vrije Universiteit Brussel - Capricorn Venture Partners leads 1st financing round of € 3 million

Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Former Becton Dickinson and Wyeth Executive Joins Merck

Movetis starts phase III clinical trial with prucalopride in male patients with chronic constipation

Voyager Therapeutics & Genzyme collaborate to develop and commercialize novel AAV gene therapies for patients with CNS Disorders

Aseptika Granted United States Patent for Biomarkers for Respiratory Infection Onset

Vertex Pharmaceuticals: Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor

Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea